Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Syndax Pharmaceuticals (NASDAQ:SNDX)Defense World · 3 days ago
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS LawGuruFocus · Oct 17, 2026
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS LawBusiness Wire · Oct 17, 2026
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 ListGlobeNewsWire · Oct 15, 2026
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalZacks Investment Research · Oct 14, 2026
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)GuruFocus · Oct 13, 2026Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.45 | -$0.55 | Miss |
| Apr 30, 2026 | -$0.59 | -$0.48 | Beat |
| Feb 26, 2026 | -$0.58 | -$0.78 | Miss |
| Nov 3, 2025 | -$0.74 | -$0.70 | Beat |
| Aug 4, 2025 | -$1.00 | -$0.83 | Beat |
| May 5, 2025 | -$1.04 | -$0.98 | Beat |